These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11144395)

  • 1. Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin.
    Guay DR
    Pediatr Infect Dis J; 2000 Dec; 19(12 Suppl):S141-6. PubMed ID: 11144395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin.
    Guay DR
    Clin Ther; 2002 Apr; 24(4):473-89. PubMed ID: 12017394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefdinir: an expanded-spectrum oral cephalosporin.
    Guay DR
    Ann Pharmacother; 2000 Dec; 34(12):1469-77. PubMed ID: 11144705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
    Sultan T; Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research and development of new oral cephems, cefixime and cefdinir].
    Sakane K; Kawabata K; Inamoto Y; Yamanaka H; Takaya T
    Yakugaku Zasshi; 1993 Sep; 113(9):605-26. PubMed ID: 8229662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftibuten: a new expanded-spectrum oral cephalosporin.
    Guay DR
    Ann Pharmacother; 1997 Sep; 31(9):1022-33. PubMed ID: 9296244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
    Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sensitivity of clinical bacteria isolated in Scotland to the oral cephalosporin, cefdinir.
    Payne DJ; Amyes SG
    Drugs Exp Clin Res; 1992; 18(6):225-31. PubMed ID: 1478161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.
    Wise R; Andrews JM; Thornber D
    J Antimicrob Chemother; 1991 Aug; 28(2):239-48. PubMed ID: 1778855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS; Karavokiros KT; Taeubel MA; Itokazu GS
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.
    Kearns GL; Young RA
    Clin Pharmacokinet; 1994 Mar; 26(3):169-89. PubMed ID: 8194281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RU 29 246, the active compound of the cephalosporin-prodrug-ester HR 916. I. Antibacterial activity in vitro.
    Bauernfeind A; Jungwirth R; Eberlein E; Klesel N; Adam F; Isert D; Limbert M; Markus A; Schrinner E; Seibert G
    J Antibiot (Tokyo); 1992 Apr; 45(4):505-20. PubMed ID: 1592683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of recent bacterial isolates to cefdinir and selected antibiotics among children with urinary tract infections.
    Bonsu BK; Shuler L; Sawicki L; Dorst P; Cohen DM
    Acad Emerg Med; 2006 Jan; 13(1):76-81. PubMed ID: 16365328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin.
    Guay DR
    Clin Ther; 2001 Dec; 23(12):1924-37; discussion 1923. PubMed ID: 11813929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of cefdinir: pharmacokinetics, safety, and efficacy in the treatment of uncomplicated skin and skin structure infections.
    París MM; Devcich KJ
    Cutis; 2004 May; 73(5 Suppl):14-8. PubMed ID: 15182160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.